New product: Phesgo (pertuzumab/trastuzumab) 600 mg/600 mg and 1200 mg/ 1200 mg solution for injection

Phesgo is licensed for use in combination with chemotherapy in neoadjuvant and adjuvant setting in treatment of HER2-positive, early breast cancer and in combination with docetaxel in HER2-positive metastatic or locally recurrent unresectable breast cancer.

Source:

electronic Medicines compendium